Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Bulk Affymetrix Exon array analysis of prostate tissues prior to treatment with neoadjuvant ADT plus enzalutamide

ABSTRACT: Bulk Affymetrix Exon array analysis of prostate tissues prior to treatment with neoadjuvant ADT plus enzalutamide

PROVIDER: PRJNA759231 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Bulk RNA-seq analysis of prostate tissues treated with neoadjuvant ADT plus enzalutamide

Project description:Bulk RNA-seq analysis of prostate tissues treated with neoadjuvant ADT plus enzalutamide

| PRJNA759198 | ENA

Bulk Affymetrix Exon array analysis of prostate tissues prior to treatment with neoadjuvant ADT plus enzalutamide

Project description:The purpose of this study was to profile bulk tissue gene expression on Affymetrix microarrays prior to therapy Processing of samples on this microarray platform enables direct comparison to thousands of previously-described specimens.

2025-08-21 | GSE183126 | GEO

Neoadjuvant Intense ADT for High Risk Prostate Cancer: Baseline Analysis

Project description:The purpose of this study was to develop better ways of detecting prostate cancer before and after pre-operative treatment, and to test the feasibility of multi parametric magnetic resonance imaging (mpMRI) for the localization and detection of focal prostate cancer both before and after pre-operative treatment with ADT and enzalutamide. In this study, patients with intermediate and high risk prostate cancer received six months of neoadjuvant intense androgen deprivation therapy prior to radical prostatectomy. Biopsies were acquired prior to treatment. Tissue from biopsy and radical prostatectomy were subjected to sequencing and analysis for determination of features associated with response or resistance to treatment.

2025-08-21 | GSE152516 | GEO

Neoadjuvant Intense ADT for High Risk Prostate Cancer

Project description:Neoadjuvant Intense ADT for High Risk Prostate Cancer

| PRJNA591229 | ENA

Neoadjuvant Intense ADT for High Risk Prostate Cancer

Project description:Neoadjuvant Intense ADT for High Risk Prostate Cancer

| PRJNA591228 | ENA

Neoadjuvant Intense ADT for High Risk Prostate Cancer: Baseline Analysis

Project description:Neoadjuvant Intense ADT for High Risk Prostate Cancer: Baseline Analysis

| PRJNA639568 | ENA

Bulk RNA-seq analysis of prostate tissues treated with neoadjuvant ADT plus enzalutamide

Project description:The purpose of this study was to identify the changes in gene expression that occur throughout the prostate in response to system therapy.

2021-12-31 | GSE183100 | GEO

Neoadjuvant Enzalutamide Prior to Prostatectomy.

Project description:Purpose: Prostate cancer is dependent on androgen receptor (AR) activation. Optimal AR antagonism may effectively cytoreduce local disease and suppress or eliminate micrometastases. We evaluated neoadjuvant therapy prior to prostatectomy with the potent AR antagonist enzalutamide (enza) either alone or in combination with dutasteride (dut) and leuprolide (enza/dut/luteinizing hormone-releasing hormone analogues [LHRHa]).Experimental Design: Forty-eight of 52 men with intermediate or high-risk localized prostate cancer proceeded to prostatectomy after neoadjuvant enzalutamide or enza/dut/LHRHa for 6 months. We assessed pathologic complete response (pCR), minimal residual disease (MRD; ≤3 mm maximum diameter of residual disease), residual cancer burden (RCB), and expression of PSA and serum and tissue androgen concentrations. We compared the proportion of patients with pCR in each treatment arm with a historical control rate of 5%, based on previous reports of flutamide with LHRHa.Results: In the enzalutamide arm, none of the 25 patients achieved pCR or MRD. In the enza/dut/LHRHa arm, one of 23 patients (4.3%) achieved pCR and 3 of 23 (13.0%) achieved MRD. Median RCB was higher in the enzalutamide arm than in the enza/dut/LHRHa arm (0.41 cm3 vs. 0.06 cm3, respectively). Tissue testosterone and dihydrotestosterone levels correlated with RCB. No adverse events leading to study drug discontinuation were reported.Conclusions: Combination therapy with enza/dut/LHRHa resulted in pCR and MRD rates comparable with historical controls. Evidence of continued AR activity in residual tumor suggests that AR signaling may contribute to survival. Strategies to more effectively ablate AR activity are warranted to determine whether more substantial antitumor effects are observed. Clin Cancer Res; 23(9); 2169-76. ©2016 AACR.

| S-EPMC5570479 | biostudies-literature

In vivo efficacy study of BMS-986365 and enzalutamide in mCRPC PDX models

Project description:This study is aimed to explore in vivo trascriptional response of BMS-986365 and enzalutamide in mCRPC PDX models CTG-2441 and CTG-2440 which were derived from bone metastases of the same patient following progression on ADT or ADT plus abiraterone treatments, respectively.

2025-07-15 | GSE298071 | GEO

Immune signature driven by ADT-induced immune microenvironment remodeling in prostate cancer is correlated with recurrence-free survival and immune infiltration

Project description:Androgen deprivation therapy (ADT) is a cornerstone treatment for locally advanced or metastatic prostate cancer (PCa). However, its potential effects on the tumor immune microenvironment (TIM) of PCa patients and the underlying mechanism remain largely unclear.We used RNA sequencing to reveal the effects of ADT on the PCa TIM at the transcriptome level. RNA sequencing was performed on 6 paired pre-ADT biopsy and post-ADT PCa lesions and 5 paired paracancerous benign tissues from patients receiving neoadjuvant ADT with locally advanced PCa.

2020-09-23 | GSE150368 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data